Viktor von Wyl
Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors
Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Battegay M, Cavassini M, Hirschel B, Garzoni C, Bürgisser P, Klimkait T, Yerly S, Böni J, von Wyl V, Swiss HIV Cohort Study (SHCS). Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2011; 57:24-31.
May 1, 2011Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors
May 1, 2011J Acquir Immune Defic Syndr 2011; 57:24-31
Scherrer Alexandra U, Günthard Huldrych F, Ledergerber Bruno, Bernasconi Enos, Vernazza Pietro, Battegay Manuel, Cavassini Matthias, Hirschel Bernard, Garzoni Christian, Bürgisser Philippe, Klimkait Thomas, Yerly Sabine, Böni Jürg, von Wyl Viktor, Swiss HIV Cohort Study (SHCS)
Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study
Fehr J, Hirschel B, Vernazza P, Martinetti G, Bernasconi E, Günthard H, Battegay M, Bucher H, Klimkait T, Fux C, Cavassini M, Glass T, Louvel S, Hamy F, Hirsch H, von Wyl V, Böni J, Yerly S, Bürgisser P, Hiv Cohort Study A. Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study. J Transl Med 2011; 9:14.
Jan 21, 2011Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study
Jan 21, 2011J Transl Med 2011; 9:14
Fehr Jan, Hirschel Bernard, Vernazza Pietro, Martinetti Gladys, Bernasconi Enos, Günthard Huldrych F, Battegay Manuel, Bucher Heiner C, Klimkait Thomas, Fux Christoph A, Cavassini Matthias, Glass Tracy R, Louvel Severine, Hamy Francois, Hirsch Hans H, von Wyl Viktor, Böni Jürg, Yerly Sabine, Bürgisser Philippe, Hiv Cohort Study And The Swiss
Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection
Kouyos R, Cavassini M, Rauch A, Battegay M, Vernazza P, Bernasconi E, Ledergerber B, Bonhoeffer S, Günthard H, Hirschel B, Weber R, Klimkait T, von Wyl V, Yerly S, Böni J, Rieder P, Joos B, Taffé P, Shah C, Bürgisser P, Swiss HIV Cohort Study. Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clin Infect Dis 2011; 52:532-9.
Jan 10, 2011Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection
Jan 10, 2011Clin Infect Dis 2011; 52:532-9
Kouyos Roger D, Cavassini Matthias, Rauch Andri, Battegay Manuel, Vernazza Pietro, Bernasconi Enos, Ledergerber Bruno, Bonhoeffer Sebastian, Günthard Huldrych F, Hirschel Bernard, Weber Rainer, Klimkait Thomas, von Wyl Viktor, Yerly Sabine, Böni Jürg, Rieder Philip, Joos Beda, Taffé Patrick, Shah Cyril, Bürgisser Philippe, Swiss HIV Cohort Study
Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA
Gianella S, Günthard H, Joos B, Weber R, Vernazza P, Hirschel B, Rauch A, Cavassini M, Bernasconi E, Battegay M, Niederoest B, Fischer M, von Wyl V, the Swiss HIV Cohort Study. Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antivir Ther 2011; 16:535-545.
Jan 1, 2011Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA
Jan 1, 2011Antivir Ther 2011; 16:535-545
Gianella Sara, Günthard Huldrych F, Joos Beda, Weber Rainer, Vernazza Pietro, Hirschel Bernard, Rauch Andri, Cavassini Matthias, Bernasconi Enos, Battegay Manuel, Niederoest Barbara, Fischer Marek, von Wyl Viktor, the Swiss HIV Cohort Study
B cells from HIV-infected patients with primary central nervous system lymphoma display an activated phenotype and have a blunted TNF-? response to TLR9 triggering
Audigé A, Schlaepfer E, von Wyl V, Miller R, Vernazza P, Nadal D, Speck R, SHCS. B cells from HIV-infected patients with primary central nervous system lymphoma display an activated phenotype and have a blunted TNF-? response to TLR9 triggering. AIDS Res Hum Retroviruses 2010; 26:1063-74.
Oct 1, 2010B cells from HIV-infected patients with primary central nervous system lymphoma display an activated phenotype and have a blunted TNF-? response to TLR9 triggering
Oct 1, 2010AIDS Res Hum Retroviruses 2010; 26:1063-74
Audigé Annette, Schlaepfer Erika, von Wyl Viktor, Miller Regina C, Vernazza Pietro, Nadal David, Speck Roberto F, SHCS
Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load
Alizon S, Bonhoeffer S, Günthard H, Telenti A, Bürgisser P, Battegay M, Bernasconi E, Vernazza P, Rauch A, Furrer H, Klimkait T, Shah C, Böni J, Hirschel B, Yerly S, Kouyos R, Stadler T, von Wyl V, Swiss HIV Cohort Study. Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS Pathog 2010; 6
Sep 30, 2010Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load
Sep 30, 2010PLoS Pathog 2010; 6
Alizon Samuel, Bonhoeffer Sebastian, Günthard Huldrych F, Telenti Amalio, Bürgisser Philippe, Battegay Manuel, Bernasconi Enos, Vernazza Pietro, Rauch Andri, Furrer Hansjakob, Klimkait Thomas, Shah Cyril, Böni Jürg, Hirschel Bernard, Yerly Sabine, Kouyos Roger D, Stadler Tanja, von Wyl Viktor, Swiss HIV Cohort Study
Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland
Kouyos R, Bonhoeffer S, Ledergerber B, Rickenbach M, Bernasconi E, Vernazza P, Battegay M, Furrer H, Cavassini M, Hirschel B, Weber R, Klimkait T, Bürgisser P, Shah C, Taffé P, Böni J, Yerly S, von Wyl V, Günthard H. Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. J Infect Dis 2010; 201:1488-97.
May 15, 2010Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland
May 15, 2010J Infect Dis 2010; 201:1488-97
Kouyos Roger D, Bonhoeffer Sebastian, Ledergerber Bruno, Rickenbach Martin, Bernasconi Enos, Vernazza Pietro, Battegay Manuel, Furrer Hansjakob, Cavassini Matthias, Hirschel Bernard, Weber Rainer, Klimkait Thomas, Bürgisser Philippe, Shah Cyril, Taffé Patrick, Böni Jürg, Yerly Sabine, von Wyl Viktor, Günthard Huldrych F
Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland
von Wyl V, Günthard H, Ledergerber B, Bonhoeffer S, Francioli P, Vernazza P, Hirschel B, Furrer H, Cavassini M, Bernasconi E, Battegay M, Klimkait T, Bürgisser P, Yerly S, Swiss HIV Cohort Study. Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009; 48:979-87.
Apr 1, 2009Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland
Apr 1, 2009Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009; 48:979-87
von Wyl Viktor, Günthard Huldrych F, Ledergerber Bruno, Bonhoeffer Sebastian, Francioli Patrick, Vernazza Pietro, Hirschel Bernard, Furrer Hansjakob, Cavassini Matthias, Bernasconi Enos, Battegay Manuel, Klimkait Thomas, Bürgisser Philippe, Yerly Sabine, Swiss HIV Cohort Study
Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir
von Wyl V, Günthard H, Ledergerber B, Rickenbach M, Vernazza P, Hirschel B, Furrer H, Cavassini M, Bernasconi E, Battegay M, Klimkait T, Bürgisser P, Böni J, Yerly S, Swiss HIV Cohort Study. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008; 46:1299-309.
Apr 15, 2008Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir
Apr 15, 2008Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008; 46:1299-309
von Wyl Viktor, Günthard Huldrych F, Ledergerber Bruno, Rickenbach Martin, Vernazza Pietro, Hirschel Bernard, Furrer Hansjakob, Cavassini Matthias, Bernasconi Enos, Battegay Manuel, Klimkait Thomas, Bürgisser Philippe, Böni Jürg, Yerly Sabine, Swiss HIV Cohort Study
Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons
Berger S, Weber R, Battegay M, Ledergerber B, Vernazza P, Regli D, Furrer H, Zellweger C, Ehlert U, von Wyl V, Schad T, Gaab J. Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. AIDS (London, England) 2008; 22:767-75.
Mar 30, 2008Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons
Mar 30, 2008AIDS (London, England) 2008; 22:767-75
Berger Simona, Weber Rainer, Battegay Manuel, Ledergerber Bruno, Vernazza Pietro, Regli Daniel, Furrer Hansjakob, Zellweger Claudine, Ehlert Ulrike, von Wyl Viktor, Schad Tanja, Gaab Jens
Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study
Wolbers M, Bucher H, Günthard H, Yerly S, Battegay M, Bernasconi E, Vernazza P, Cavassini M, Furrer H, Hirschel B, von Wyl V, Opravil M, Swiss HIV Cohort Study. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. AIDS (London, England) 2007; 21:2201-7.
Oct 18, 2007Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study
Oct 18, 2007AIDS (London, England) 2007; 21:2201-7
Wolbers Marcel, Bucher Heiner C, Günthard Huldrych, Yerly Sabine, Battegay Manuel, Bernasconi Enos, Vernazza Pietro, Cavassini Matthias, Furrer Hansjakob, Hirschel Bernard, von Wyl Viktor, Opravil Milos, Swiss HIV Cohort Study
Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types
von Wyl V, Günthard H, Ledergerber B, Perrin L, Rickenbach M, Bernasconi E, Vernazza P, Hirschel B, Telenti A, Furrer H, Battegay M, Klimkait T, Bürgisser P, Böni J, Yerly S, for the Swiss HIV Cohort Study. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Archives of internal medicine 2007; 167:1782-90.
Sep 10, 2007Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types
Sep 10, 2007Archives of internal medicine 2007; 167:1782-90
von Wyl Viktor, Günthard Huldrych F, Ledergerber Bruno, Perrin Luc, Rickenbach Martin, Bernasconi Enos, Vernazza Pietro, Hirschel Bernard, Telenti Amalio, Furrer Hansjakob, Battegay Manuel, Klimkait Thomas, Bürgisser Philippe, Böni Jürg, Yerly Sabine, for the Swiss HIV Cohort Study
Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study
Zinkernagel A, Weber R, Schmid P, Bernasconi E, Opravil M, Tarr P, Hirschel B, Battegay M, Furrer H, Rickenbach M, Ledergerber B, von Wyl V, Swiss HIV Cohort Study. Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antiviral therapy 2006; 11:131-42.
Jan 1, 2006Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study
Jan 1, 2006Antiviral therapy 2006; 11:131-42
Zinkernagel Annelies S, Weber Rainer, Schmid Patrick, Bernasconi Enos, Opravil Milos, Tarr Philip E, Hirschel Bernard, Battegay Manuel, Furrer Hansjakob, Rickenbach Martin, Ledergerber Bruno, von Wyl Viktor, Swiss HIV Cohort Study